A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Cancer Cell

Volumn 9, Issue 5, 2006, Pages 341-349

  Fan, Qi Wen ^a,b   Knight, Zachary A ^c   Goldenberg, David D ^a,b   Yu, Wei ^a   Mostov, Keith E ^a   Stokoe, David ^c   Shokat, Kevan M ^a,b,c   Weiss, William A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CELLCYCLE; CHEMBIO; SIGNALING

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DIMETHYL SULFOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PI 103; PI 85; PIK 108; PIK 112; PIK 124; PIK 39; PIK 64; PIK 73; PIK 85; PIK 90; PIK 93; PROTEIN KINASE B; PROTEIN P110; PROTEIN P53; RAPAMYCIN; TGX 115; TGX 286; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; GLIOMA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALIA; MAMMALIA;

EID: 33646382364     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.03.029     Document Type: Article

References (45)

1. Agosti R.M., Leuthold M., Gullick W.J., Yasargil M.G., and Wiestler O.D. Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Arch. A Pathol. Anat. Histopathol. 420 (1992) 321-325
2. Aguirre V., Uchida T., Yenush L., Davis R., and White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275 (2000) 9047-9054
3. Aoki M., and Vogt P.K. Retroviral oncogenes and TOR. Curr. Top. Microbiol. Immunol. 279 (2004) 321-338
4. Bachman K.E., Argani P., Samuels Y., Silliman N., Ptak J., Szabo S., Konishi H., Karakas B., Blair B.G., Lin C., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3 (2004) 772-775
5. Brachmann S.M., Ueki K., Engelman J.A., Kahn R.C., and Cantley L.C. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25 (2005) 1596-1607
6. Broderick D.K., Di C., Parrett T.J., Samuels Y.R., Cummins J.M., McLendon R.E., Fults D.W., Velculescu V.E., Bigner D.D., and Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64 (2004) 5048-5050
7. Byfield M.P., Murray J.T., and Backer J.M. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280 (2005) 33076-33082
8. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 4240-4245
9. Choo A.Y., and Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell 9 (2006) 77-79
10. Czauderna F., Fechtner M., Aygun H., Arnold W., Klippel A., Giese K., and Kaufmann J. Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res. 31 (2003) 670-682
11. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91 (2004) 1-30
12. Easton J.B., and Houghton P.J. Therapeutic potential of target of rapamycin inhibitors. Expert Opin. Ther. Targets 8 (2004) 551-564
13. Ekstrand A.J., Sugawa N., James C.D., and Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 89 (1992) 4309-4313
14. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
15. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
16. Fan Q.W., Zhang C., Shokat K.M., and Weiss W.A. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr. Biol. 12 (2002) 1386-1394
17. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
18. Gupta N., Scharenberg A.M., Fruman D.A., Cantley L.C., Kinet J.P., and Long E.O. The SH2 domain-containing inositol 5′-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcγRIIb1-mediated inhibition of B cell receptor signaling. J. Biol. Chem. 274 (1999) 7489-7494
19. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., and Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177-189
20. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
21. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
22. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37 (2005) 19-24
23. Jackson S.P., Schoenwaelder S.M., Goncalves I., Nesbitt W.S., Yap C.L., Wright C.E., Kenche V., Anderson K.E., Dopheide S.M., Yuan Y., et al. PI 3-kinase p110β: a new target for antithrombotic therapy. Nat. Med. 11 (2005) 507-514
24. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175
25. Knight Z.A., and Shokat K.M. Features of selective kinase inhibitors. Chem. Biol. 12 (2005) 621-637
26. Knight Z.A., Chiang G.G., Alaimo P.J., Kenski D.M., Ho C.B., Coan K., Abraham R.T., and Shokat K.M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12 (2004) 4749-4759
27. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., et al. A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell 125 (2006) in press
28. Korzeniewski C., and Callewaert D.M. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64 (1983) 313-320
29. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 (2005) 172-187
30. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., and Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10 (2002) 457-468
31. Lowndes N.F., and Toh G.W. DNA repair: The importance of phosphorylating histone H2AX. Curr. Biol. 15 (2005) R99-R102
32. Margolin K., Longmate J., Baratta T., Synold T., Christensen S., Weber J., Gajewski T., Quirt I., and Doroshow J.H. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104 (2005) 1045-1048
33. Nobukuni T., Joaquin M., Roccio M., Dann S.G., Kim S.Y., Gulati P., Byfield M.P., Backer J.M., Natt F., Bos J.L., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. USA 102 (2005) 14238-14243
34. Rao R.D., and James C.D. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin. Oncol. 31 (2004) 595-604
35. Sadhu C., Dick K., Tino W.T., and Staunton D.E. Selective role of PI3Kδ in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 308 (2003) 764-769
36. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
37. Schlegel J., Merdes A., Stumm G., Albert F.K., Forsting M., Hynes N., and Kiessling M. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int. J. Cancer 56 (1994) 72-77
38. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., and Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
39. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., and Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65 (2005) 3336-3346
40. Ueki K., Fruman D.A., Brachmann S.M., Tseng Y.H., Cantley L.C., and Kahn C.R. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell. Biol. 22 (2002) 965-977
41. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
42. Wong A.J., Ruppert J.M., Bigner S.H., Grzeschik C.H., Humphrey P.A., Bigner D.S., and Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 89 (1992) 2965-2969
43. Wong S., McLaughlin J., Cheng D., Zhang C., Shokat K.M., and Witte O.N. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc. Natl. Acad. Sci. USA 101 (2004) 17456-17461
44. Wymann M.P., Zvelebil M., and Laffargue M. Phosphoinositide 3-kinase signalling-which way to target?. Trends Pharmacol. Sci. 24 (2003) 366-376
45. Zheng X.F., Florentino D., Chen J., Crabtree G.R., and Schreiber S.L. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82 (1995) 121-130